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osting by EAbstract The objective of the study is to investigate the alcoholic (AlcE) and aqueous (AqsE)
extracts of stem bark of Erythrina indica (Papilionaceae) for hypoglycaemic effects in normal and
diabetic rats. Diabetes was induced in rats by a single dose administration of alloxan (120 mg/
kg, i.p.) or by injecting dexamethasone (10 mg/kg, i.p.) for 10 days. In normal rats, AlcE and AqsE
had signiﬁcantly decreased the blood glucose level (BGL) in a dose dependent manner after
repeated administration for 7 days. In alloxan-induced diabetic rats, both the extracts decreased
blood sugar levels with signiﬁcant improvement in glucose tolerance and body weight at the end
of 1st, 2nd and 3rd week after test extract treatment. In case of dexamethasone induced insulin resis-
tant diabetic rats, repeated administration of AlcE and AqsE inhibited the increase in blood glucose
level and improved glucose tolerance induced by dexamethasone as compared to dexamethasone
induced diabetic rats. These results suggest that both extracts possess hypoglycaemic activity in nor-
mal as well as in diabetic rats. Among AlcE and AqsE, AqsE possesses better hypoglycaemic activ-0 2922482x189; fax: +91 820
fmail.com (K. Nandakumar).
y. Production and hosting by
Saud University.
lsevier
36 A.Y. Kumar et al.ity than AlcE in all the models. Preliminary phytochemical investigations revealed that alcoholic
extracts contain carbohydrates, alkaloids, ﬂavonoids, saponins, phytosterols, phenolics and tan-
nins. Aqueous extract contains carbohydrates, alkaloids, ﬂavonoids, glycosides, phytosterols and
triterpenoids. These phytoconstituents may be responsible for the hypoglycaemic activity of the
plant.
ª 2010 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Diabetes mellitus is a metabolic disorder characterized by
hyperglycaemia and alterations in carbohydrate, lipid and pro-
tein metabolism, associated with absolute or relative deﬁcien-
cies in insulin secretion and/or insulin action (Valiathan,
1998). The World Health Organization (WHO) estimates that
more than 220 million people worldwide have diabetes and this
number is likely to more than double by 2030 (WHO, 2009).
The high prevalence of diabetes as well as its long-term compli-
cations has led to an ongoing search for hypoglycaemic agents
(Nicasio et al., 2005).
The treatment of hyperglycaemia in diabetic patients is di-
rected towards achieving euglycemia and minimizes chronic
complications by administering oral hypoglycaemic agents.
Despite this, the steady rise of insulin resistance cases of NID-
DM is causing grave concern among the physicians. Although
a number of pharmacological approaches to the treatment of
NIDDM are currently available, it is clear that none is ideal
for the treatment of a great majority of NIDDM patients.
Thus development of newer therapeutic approach remains
highly desirable (Rao and Rao, 2001). In view of the side ef-
fects associated with the treatment by insulin and synthetic
drugs which are available at present, searching for effective
and safer hypoglycaemic plant drugs is going on all over the
world. Herbal medicines play a vital role in this part to prevent
side effects (Suman et al., 2006).
In the traditional system of Ayurvedic treatment, medicines
consist of plant products, either a single drug or in combina-
tion with others, which are considered to be less toxic and
are free from side effects compared to synthetic drugs. Since
the time of Charka and Sushruta many herbal medicines have
been recommended for the treatment of diabetes mellitus.
The fresh juice from the bark of Erythrina indica (Papilion-
aceae) is used by the tribals for the treatment of diabetes
(Nadkarni and Nadkarni, 2000). Recently, investigation on
the plantE. indica indicates that it is used in Cameroonian folk
medicine for the treatment of analgesic and microbial infec-
tions and was found to exhibit signiﬁcant anticonvulsant and
anxiolytic activity (Nkengfack et al., 2001; Pitchaiah et al.,
2008). The present study was aimed to perform a systematic
study and to investigate the possible hypoglycaemic and anti-
diabetic activities of various extracts of E. indica in normal
and in experimentally induced diabetes rats.2. Materials and methods
2.1. Drugs
Glibenclamide tab. (Aventis Pharma Ltd., Mumbai, India);
alloxan (Sigma–Aldrich, USA); dexamethasone sodium phos-
phate (Tridoss Laboratories Ltd., Mumbai, India); glucoseestimation kit. (Span diagnostic Ltd., Surat, India) were used
in this study. All the other solvents and chemicals used for
extraction and phytochemical investigation were of analytical
grade purchased from S.D. Fine Chemicals Pvt. Ltd., Mum-
bai, India.
2.2. Animals
Adult Wistar rats weighing (150–200 g) from Bioneeds, Neel-
amangla, Bangalore were used. All the animals were housed
in the animal house of PES College of Pharmacy, Bangalore,
and were maintained at a standard room temperature of
25 ± 1 C; relative humidity of 45–55% and a 12:12 h light/
dark cycle for 7 days with free access to standard rat pellet
(Pranav Agro Industries Ltd., Bangalore, India) and water
ad libitum under hygienic conditions. The animals were se-
lected based on the model criteria and care was taken in such
a way that all the animals were used only once. Animals were
accustomed to laboratory conditions for 48 h before the initi-
ation of experiment. The approval of the Institutional Animal
Ethical Committee (IAEC) of PES College of Pharmacy, Ban-
galore (Karnataka) was taken before the initiation of the
experiments. All the protocols and experiments were con-
ducted in compliance with the ethical principles and guidelines
provided by the Committee for the Purpose of Control and
Supervision of Experiments on Animals (CPCSEA), Chennai,
India.
2.3. Preparation of extracts
Stem barks of E. indica Linn. were collected and was authen-
ticated by Shiddamallayya N, Regional Research Institute
(RRI), Jayanagar, Bangalore. The air-dried powdered material
of 80 g was successively extracted by using Soxhlet apparatus,
at 60–80 C with petroleum ether followed by alcohol (70%).
The residue obtained from the ﬁrst extract was air dried and
then subjected for alcoholic extract.
Residue obtained from the alcoholic extract was then mac-
erated with water for 72 h. All the extracts were then concen-
trated by distilling the solvent evaporating to dryness at low
temperature. The extracts were weighed and the percentages
of different extractive values were calculated in terms of air
dried weight of the plant material.
2.4. Determination of acute toxicity (OECD, 2001)
The acute toxicity of alcoholic and aqueous extracts of E. indi-
ca were determined by using female albino Wistar rats (150–
200 g) which were maintained under the standard conditions.
The animals (n= 5 per dose) were fasted 12 h prior to the
experiment, up and down procedures were adopted for toxicity
studies. Animals were administered with single dose of extract
of E. indica at a dose of 2000 mg/kg and observed for their
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ity and the dose increased up to 5000 mg/kg and were observed
up to 7 days for their behavioural, economical and neurologi-
cal proﬁles except slight depression in their activity.
2.5. Assessment of hypoglycaemic activity in normal rats
(Kesari et al., 2006)
Fasted rats were divided in to ﬁve groups consisting of six ani-
mals in each group. Groups 1 and 2 received distilled water
and vehicle (3% (v/v) Tween 80 in distilled water), orally in
a volume of 10 ml/kg, which served as normal control and
vehicle control. Group 3 received Glibenclamide (5 mg/kg,
p.o.) as a standard drug suspended in vehicle. AlcE and AqsE
suspended in vehicle were administered at the doses of 200 and
400 m/kg, p.o. in a volume of 10 ml/kg to the rats of groups 4,
5, 6 and 7, respectively. Blood samples were collected from the
tail vein or by retro-orbital puncture method just prior to and
at 1, 2 and 4 h after dosing for acute studies and glucose was
estimated. For sub-acute studies blood sample was removed
on the 4th and 7th days after 16 h of overnight fasting for glu-
cose level estimation.
Oral glucose tolerance test (OGTT) was carried by admin-
istering glucose (2 g/kg, p.o.), 30 min after the extract or stan-
dard drug administration after 7 days of pre-treatment period.
Blood samples were collected from tail vein for glucose analy-
sis prior to glucose administration (0 h) and at 1, 2 and 3 h
after glucose loading.
2.6. Assessments of anti-diabetic activity in alloxan-induced
diabetic rats (Kesari et al., 2006)
Alloxan monohydrate was dissolved in saline and administered
intravenously into fasted rats at a dose of 120 mg/kg body wt.
The solution should be fresh and prepared just prior to the
administration. The rats were given 5% (w/v) glucose solution
in feeding bottles for next 24 h in their cages to prevent hypo-
glycaemia after alloxan injection. After 72 h rats with BGL
greater than 200 mg/dl and less than 400 mg/dl were selected
and observed for consistent hyperglycaemia (fasting blood glu-
cose level greater than 200 mg/dl and lesser then 400 mg/dl) up
to 7 days. Such animals were divided into seven groups as
follows:
Group 1: Normal control (distilled water 10 ml/kg, p.o.).
Group 2: Vehicle control (3% (v/v) Tween 80 in water
10 ml/kg, p.o.).
Group 3: Standard group (Glibenclamide 10 mg/kg, p.o.).
Group 4: AlcE 200 group (alcoholic extract 200 mg/kg,
p.o.).
Group 5: AlcE 400 group (alcoholic extract 400 mg/kg,
p.o.).
Group 6: AqsE 200 group (aqueous extract 200 mg/kg,
p.o.).
Group 7: AqsE 400 group (aqueous extract (400 mg/kg,
p.o.).
Blood samples were collected by retro-orbital puncture at 0,
1, 2, 4 and 8 h after the administration. The treatment was con-
tinued for the next 21 days and blood samples were collected
on 4th, 7th, 14th and 21st days after 1 h administration. Blood
glucose level (BGL) was estimated at various time intervalsGOD/P.O.D. kit. Oral glucose tolerance test (OGTT) on day
21 was carried out. Body weight of all animals was measured
on the 0, 4th, 7th, 14th and 21st days after 1 h of treatment
with the extracts/Glibenclamide/vehicle. The percentage
change of body weight was calculated from its initial weight.
Urine strip for glucose estimation contains 1.7% (w/w) glu-
cose oxidase, 0.2% (w/w) peroxidase, 0.1% (w/w) potassium
iodide, 71.8% buffer, 42.1% (w/w) non-reactive ingredients.
Urine was collected on day 4, 7, 15 and 21 after administration
of extracts/Glibenclamide/vehicle. The sugar level in urine was
graded (DICL, Chennai). The colour intensity of strip depends
on the concentration of glucose which was compared against
the standard grade given on the packet.
2.6.1. Assessment of mortality rate in alloxan-induced diabetic
rats
Alloxan may cause severe ketoacidosis and may lead to death
of animal. In view of this the mortality rate was monitored
throughout the study. The % of mortality was calculated at
the end of each week of treatment on 7th, 14th, 21st day.
2.7. Effect of E. indica extracts on dexamethasone induced
insulin resistant diabetic rats (Shalam et al., 2006)
Wistar rats of either sex weighing 170–220 g were divided into
seven groups consisting of six animals per group. Groups 1
and 2 received only distilled water and vehicle (3% (v/v) Tween
80 in water). Group 3 received Glibenclamide (10 mg/kg, p.o.)
which served as reference standard group. AqsE at the doses,
200 and 400 mg/kg were administered orally to the rats of
groups 4 and 5, respectively. All the treatments were made
for a period of 10 days. One hour after the test drug adminis-
tration all the rats received dexamethasone (10 mg/kg, p.o.)
daily for 10 days except group 1 which served as the normal
control group. Blood samples were withdrawn from tail vein,
to determine FBG and insulin levels, prior to and on 4th,
7th and 10th days after 1 h after dexamethasone treatment.
Oral glucose tolerance test was also performed with a glucose
loading in these rats on the 10th day.
2.8. Statistical analysis
The values were expressed as mean ± S.E.M. Data were ana-
lyzed using One-way ANOVA followed by Tukey test. One set
of comparison was made. P value <0.05 was considered as
signiﬁcant.3. Results
3.1. Preliminary phytochemical of E. indica
Phytochemical investigation of E. indica revealed that petro-
leum ether extract contains phytosterols and ﬁxed oils. AlcE
contains carbohydrates, alkaloids, ﬂavonoids, saponins, phy-
tosterols, phenolics and tannins, proteins and amino acids,
ﬁxed oils and fats. AqsE contains carbohydrates, alkaloids,
ﬂavonoids, glycosides, phytosterols, triterpenoids proteins
and amino acids. The percentage yield of petroleum ether, alco-
holic and aqueous extract were found to be 0.57, 9.5 and 5.87,
respectively. The % yield of petroleum ether extract was not
sufﬁcient. Hence was not used for further experimentation.
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Fasting blood glucose (FBG) levels were within the range of
95–105 mg/dl in all the groups at 0 h. Single dose administra-
tion of AlcE and AqsE (200 and 400 mg/kg) did not signiﬁ-
cantly decrease the blood glucose level at various time
intervals viz. 1, 2 and 4 h after treatment, indicating that the ex-
tracts could not produce signiﬁcant hypoglycaemic activity
after acute treatment (Table 1). Repeated administration of
AlcE and AqsE had signiﬁcantly reduced the FBG on 4th
day with 400 mg/kg and on 7th day with 200 and 400 mg/kg,
indicating that the aqueous extract can produce hypoglycaemia
on repeated administration (Table 2). Glibenclamide (5 mg/kg)
signiﬁcantly reduced blood glucose level after single dose and
repeated dose administration as compared to vehicle groups.
Administration of glucose (2 g/kg) to 7 days pretreated rats
signiﬁcantly suppresses the rise in BGL with AqsE at 1 and 2 h
with 200 and 400 mg/kg and at 1 h with 200 mg/kg as com-
pared with vehicle control. Glibenclamide (5 mg/kg) showed
signiﬁcant suppression in BGL rise at 1 and 2 h (Table 3).
3.3. Anti-diabetic activity in alloxan-induced diabetic rats
Fasting blood glucose (FBG) levels in normal rats were in the
range of 95–100 mg/dl. Treatment with alloxan (120 mg/kg,
i.v.) had increased the blood glucose level (BGL) to a range
of 250–270 mg/dl after 5 days. Single dose administration of
AlcE and AqsE (200 and 400 mg/kg) did not signiﬁcantly re-
duced the BGL in alloxan-induced diabetic rats, while Gliben-
clamide (5 mg/kg) signiﬁcantly reduce the BGL at 1st, 2nd andTable 1 Effect of extracts of Erythrina indica by single dose admin
Treatment Dose (mg/kg) Blood gluco
0 h
Normal control 97.28 ± 2.0
Control (3% (v/v) Tween 80) 10 ml/kg 98.01 ± 1.6
Glibenclamide 10 99.99 ± 2.1
AlcE 200 96.82 ± 0.7
AlcE 400 97.61 ± 0.8
AqsE 200 99.60 ± 1.4
AqsE 400 98.41 ± 1.1
Values are expressed as mean ± S.E.M. n= 6. P values were analysed u
* P< 0.05 versus the vehicle treated control group.
Table 2 Hypoglycaemic activity of Erythrina indica in normal rats
Treatment Dose (mg/kg) B
0
Normal control – 9






Values are expressed as mean ± S.E.M. n= 6. P values were analysed u
* P< 0.05 versus the vehicle treated control group.4th hour after single dose administration in alloxan-induced
diabetic rats (Table 4).
Repeated dose administration with alcoholic and aqueous
extract (200 and 400 mg/kg) had progressively reduced the
BGL in a dose dependent manner over a period of 3 weeks
(Table 5). However, animals treated with both the doses of
alcoholic extracts showed a signiﬁcant decrease (P< 0.05) in
BGL on 4th, 7th, 14th and 21st days of treatment when com-
pared to other groups of animals; similarly animals treated
with aqueous extracts also showed a signiﬁcant (P< 0.05) de-
crease in BGL compare to other groups. The data in Table 5
show that the aqueous extracts treatment for 21 days in dia-
betic rats has caused a reduction in BGL when compared to
the alcoholic extract, indicating the potency of aqueous ex-
tract. These results indicate that E. indica possesses hypogly-
caemic activity on repeated administration in alloxan-
induced diabetic rats.
Repeated dose treatment with AlcE and AqsE (200 and
400 mg/kg, p.o.) for 3 weeks had signiﬁcantly improved glu-
cose tolerance as compared to diabetic control rats (Table 6).
Treatment with alloxan (120 mg/kg, i.v.) had signiﬁcantly de-
creased the body weight at the end of 7th, 14th and 21st days
as compared to normal animals. Repeated administration of
Glibenclamide (5 mg/kg) had prevented the reduction in body
weight on 4th, 7th, 14th and 21st day in diabetic rats. These
results concluded that AqsE (200 and 400 mg/kg) and AlcE
at 400 mg/kg were able to signiﬁcantly inhibit the body weight
only after the 14th day, whereas with AlcE 200 mg/kg, a signif-
icant decrease in body weight was seen on the 21st day (Table
7).istration on fasting blood glucose level in normal rats.
se level (mg/dl)
1 h 2 h 4 h
96.94 ± 1.0 97.27 ± 1.98 96.6 ± 1.81
7 97.61 ± 1.50 98.8 ± 1.81 98.41 ± 1.80
2 98.41 ± 1.91 83.33 ± 1.37* 71.82 ± 1.13*
9 96.42 ± 1.46 96.82 ± 1.32 96.03 ± 0.79
6 96.82 ± 1.46 96.82 ± 1.80 96.03 ± 1.81
3 98.80 ± 1.33 97.61 ± 1.37 96.02 ± 1.91
7 98.41 ± 1.58 97.61 ± 1.73 96.42 ± 1.81
sing One-way ANOVA followed by post hoc Dunnett’s test.
after repeated dose administration for 7 days.
lood glucose level (mg/dl)
day 4th day 7th day
7.28 ± 2.0 96.59 ± 1.32 95.23 ± 1.29
8.01 ± 1.67 99.99 ± 1.62 100.79 ± 1.17
9.99 ± 2.12 57.93 ± 1.46* 53.57 ± 1.33*
8.41 ± 1.17 94.04 ± 1.02 90.07 ± 2.25*
8.41 ± 1.3 91.59 ± 1.82* 86.50 ± 1.80*
9.60 ± 1.43 88.77 ± 1.91* 82.14 ± 1.81*
98.3 ± 1.21 88.09 ± 2.21* 77.26 ± 1.86*
sing One-way ANOVA followed by post hoc Dunnett’s test.
Table 3 Effect of Erythrina indica on blood glucose level of glucose loaded hyperglycaemic rats (OGTT) after 7 days treatment.
Treatment Dose (mg/kg) Blood glucose level (mg/dl)
0 h 1 h 2 h 3 h
Normal control – 99.99 ± 2.44 145.17 ± 4.06 121.42 ± 2.74 103.73 ± 2.74
Control (3% (v/v) Tween 80) 10 ml/kg 99.52 ± 1.45 151.98 ± 1.67 123.40 ± 1.43 103.56 ± 1.59
Glibenclamide 10 55.15 ± 1.29 73.01 ± 2.0* 63.88 ± 1.43* 56.34 ± 1.46
AlcE 200 86.10 ± 1.67 122.60 ± 2.10* 103.17 ± 2.0* 89.28 ± 2.01
AlcE 400 77.77 ± 1.70 110.23 ± 2.10 92.3 ± 1.37* 80.15 ± 1.70
AqsE 200 81.74 ± 3.34 113.59 ± 4.12* 96.42 ± 3.82* 84.12 ± 3.34
AqsE 400 70.90 ± 1.63 95.23 ± 2.30* 82.93 ± 1.67* 72.61 ± 0.39
Values are expressed as mean ± S.E.M. n= 6. P values were analysed using One-way ANOVA followed by post hoc Dunnett’s test.
* P< 0.05 versus the vehicle treated control group.
Table 4 Effect of single dose treatment of Erythrina indica of blood glucose level on alloxan-induced diabetic rats.
Treatment Dose (mg/kg) Blood glucose level (mg/dl)
0 h 1 h 2 h 4 h
Normal control – 97.28 ± 2.11* 96.94 ± 1.24 97.28 ± 2.35* 96.60 ± 1.55*
Control (3% (v/v) Tween 80) 10 ml/kg 262.79 ± 7.70 266.07 ± 6.15 267.14 ± 6.42 257.86 ± 5.84
Glibenclamide 10 266.43 ± 5.90 240 ± 5.95* 203.57 ± 6.88* 172.14 ± 3.99*
AlcE 200 252.14 ± 4.38 249 ± 4.88 250.71 ± 4.03 250 ± 3.64
AlcE 400 263.21 ± 4.62 262.5 ± 4.43 255.35 ± 3.65 257.14 ± 4.02
AqsE 200 259.28 ± 5.77 257.85 ± 6.63 258.57 ± 3.84 252.5 ± 4.60
AqsE 400 264.64 ± 4.85 263.21 ± 4.96 262.85 ± 6.0 260.35 ± 5.51
Values are expressed as mean ± S.E.M. n= 6. P values were analysed using One-way ANOVA followed by post hoc Tukey’s test.
* P< 0.05 versus the vehicle treated control group.
Table 5 Effect of repeated dose treatment of Erythrina indica of blood glucose level in alloxan-induced diabetic rats.
Treatment Dose (mg/kg) Blood glucose level (mg/dl)
0 day 7th day 14th day 21st day
Normal control 97.28 ± 2.11* 96.62 ± 1.56* 96.54 ± 1.03* 97.14 ± 0.65*
Control (3% (v/v) Tween 80) 10 ml/kg 262.79 ± 7.70 280.0 ± 4.70 288.50 ± 3.70 291.25 ± 3.66
Glibenclamide 10 266.43 ± 5.90 104.64 ± 2.91* 97.14 ± 1.27* 89.64 ± 3.01*
AlcE 200 259.28 ± 2.54 195.83 ± 3.14* 189.16 ± 2.20* 167.5 ± 1.76*
AlcE 400 263.21 ± 4.91 188.57 ± 4.39* 172.08 ± 3.45* 149.5 ± 4.35*
AqsE 200 259.28 ± 5.32 156.66 ± 2.28* 137.91 ± 2.49* 130 ± 1.79*
AqsE 400 264.64 ± 5.24 143.21 ± 3.72* 125.83 ± 4.61* 115.83 ± 2.85*
Values are expressed as mean ± S.E.M. n= 6. P values were analysed using One-way ANOVA followed by post hoc Tukey’s test.
* P< 0.05 versus the vehicle treated control group.
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duced mortality of 43% over a period of 3 weeks. Repeated
administration of Glibenclamide (5 mg/kg) had prevented the
mortality in alloxan-induced diabetic rats throughout the
study. Repeated dose administration of AlcE (200 and
400 mg) showed mortality of 29% while AqsE at 400 mg/kg
dose level showed 14% mortality rate at the end of 3 weeks.
These results indicated that Glibenclamide and E. indica could
protect the animals against alloxan induced mortality.
3.3.1. Urine sugar grade in alloxan-induced diabetic rats
After administering the alloxan at a single dose of (120 mg/kg,
i.v.) the urine sugar level was grade 1 (+++) after 7 days and
it was raised to grade 2 (++++) within a week’s period. The
standard Glibenclamide had reduced the urine sugar level fromgrade 0.25 (+) to grade 0.1 (+/2) on the 7th day and no sugar
on the 14th and 21st days. In case of the AqsE (400 mg/kg) the
urine sugar level was reduced from grade 0.25 (+) to grade 0.1
(+/2) on the 14th day and on the 21st day no urine sugar level
was found. The results are summarized in Table 8.
3.4. Effect of extracts of E. indica on BGL on repeated dose
administration in dexamethasone induced insulin resistance
diabetes in rats
Administration of dexamethasone for 10 days found to signif-
icantly increase serum glucose level from 140 to 200 mg/dl
compared to normal control. The aqueous extract 200 mg/kg
along with dexamethasone for 10 days had signiﬁcantly
(P< 0.05) reduced BGL on 4th, 7th and 10th days compared
Table 6 Effect of repeated dose administration of Erythrina indica on oral glucose tolerance test in alloxan-induced diabetic rats on
21st day.
Treatment Dose (mg/kg) Blood glucose level (mg/dl)
1 h 2 h 3 h
Normal control – 142.14 ± 3.15 115.36 ± 2.70* 99.29 ± 2.02*
Control (3% (v/v) Tween 80) 10 ml/kg 443.13 ± 6.43 371.25 ± 3.90 310 ± 6.03
Glibenclamide 10 107.86 ± 3.01* 95.36 ± 3.55* 88.21 ± 3.26*
AlcE 200 217 ± 4.9* 191.5 ± 3.63* 160.5 ± 3.56*
AlcE 400 209 ± 4.09* 183.5 ± 4.46* 157 ± 3.86*
AqsE 200 167.08 ± 2.18* 142.5 ± 1.69* 129 ± 1.62*
AqsE 400 150.41 ± 3.40* 132.91 ± 2.76* 121.66 ± 2.65*
Values are expressed as mean ± S.E.M. n= 6. P values were analysed using One-way ANOVA followed by post hoc Tukey’s test.
* P< 0.05 versus the vehicle treated control group.
Table 7 Effect of repeated dose treatment of Erythrina indica of body weight in alloxan-induced diabetic rats.
Treatment Dose (mg/kg) Body weight (percentage change from the initial weight)
4 days 7 days 14 days 21 days
Normal control – 1.46 ± 0.55* 2.59 ± 0.87* 4.53 ± 1.13* 5.88 ± 0.93*
Control (3% (v/v) Tween 80) 10 ml/kg 5.48 ± 0.92 8.66 ± 1.23 10.15 ± 0.80 10.75 ± 1.19
Glibenclamide 10 1.61 ± 0.33* 2.6 ± 0.45* 2.49 ± 0.45* 2.32 ± 0.57*
AlcE 200 5.24 ± 0.48 7.58 ± 0.49 8.51 ± 0.61 7.96 ± 0.85*
AlcE 400 4.54 ± 0.62 6.85 ± 0.54 7.8 ± 0.54* 7.10 ± 1.34*
AqsE 200 4.88 ± 0.52 6.68 ± 1.0 7.66 ± 0.57* 6.60 ± 1.40*
AqsE 400 3.76 ± 0.59 6.24 ± 0.82 6.82 ± 0.71* 5.81 ± 0.82*
Values are expressed as mean ± S.E.M. n= 6. P values were analysed using One-way ANOVA followed by post hoc Tukey’s test.
* P< 0.05 versus the vehicle treated control group.
Table 8 Urine sugar grade in alloxan-induced diabetic rats after repeated administration.
Treatment Dose (mg/kg) Urine sugar (grade)
4 days 7 days 15 days 21 days
Normal control – 0 0 0 0
Control (3% (v/v) Tween 80) 10 ml/kg +++ ++++ ++++ ++++
Glibenclamide 10 + +/2 0 0
AlcE 200 +++ +++ ++ ++
AlcE 400 +++ +++ ++ ++
AqsE 200 +++ ++ + +
AqsE 400 ++ + +/2 0
Values are expressed as mean grade ± S.E.M. n= 6.
++++= 2. +++= 1. ++= 0.5. += 0.25. +/2 = 0.1.
Table 9 Effect of Erythrina indica of blood glucose level in dexamethasone induced diabetic rats.
Treatment Dose (mg/kg) Blood glucose level (mg/dl)
4th day 10th day
Normal control – 101.79 ± 2.36* 99.64 ± 1.58*
Vehicle control (3% (v/v) Tween 80) 10 ml/kg 159.38 ± 3.26 213.75 ± 4.56
Glibenclamide 10 103.93 ± 3.49* 68.21 ± 1.70*
AqsE 200 133.92 ± 0.99 130.35 ± 1.84*
AqsE 400 117.14 ± 1.14* 91.78 ± 1.05*
Values are expressed as mean ± S.E.M. n= 6. P values were analysed using One-way ANOVA followed by post hoc Dunnett’s test.
* P< 0.05 versus the vehicle treated control group.
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Table 10 Effect of repeated dose administration of AqsE on oral glucose tolerance test in dexamethasone induced diabetic rats on
10th day.
Treatment Dose (mg/kg) Blood glucose level (mg/dl)
1 h 2 h 3 h
Normal control 147.86 ± 3.91 117.86 ± 2.00* 100.71 ± 1.52*
Control (3% (v/v) Tween 80) 10 ml/kg 346.56 ± 2.63 303.13 ± 4.45 281.25 ± 3.66
Glibenclamide 10 86.79 ± 2.30* 73.19 ± 1.95* 67.14 ± 1.68*
AqsE 200 190.71 ± 1.71* 164.28 ± 2.29* 140 ± 2.18*
AqsE 400 127.14 ± 1.27* 108.57 ± 1.42* 94.28 ± 1.05*
Values are expressed as mean ± S.E.M. n= 6. P values were analysed using One-way ANOVA followed by post hoc Dunnett’s test.
* P < 0.05 versus the vehicle treated control group.
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aqueous extract 400 mg/kg reduced more signiﬁcantly
(P< 0.05) in glucose level at the 10th day compare to other
groups (Table 9). The aqueous extracts (200 and 400 mg/kg)
on repeated administration signiﬁcantly reduced the increase
in BGL in OGTT at 1, 2, 3 and 6 h compared to other groups
(Table 10).
3.4.1. Change in body weight in dexamethasone induced diabetic
rats
Dexamethasone caused weight reduction which was prevented
signiﬁcantly (P< 0.05) by the aqueous (200 and 400 mg/kg)
extract of E. indica after 10 days of treatment compared with
diabetic control and standard Glibenclamide treated animals.
4. Discussion
The present study was aimed at discovering the anti-diabetic
properties of E. indica in alloxan induced diabetes and dexa-
methasone induced insulin resistance. In the ancient daysE. in-
dica was used alone or in combination with other remedial
measures against diabetes mellitus.
Alloxan causes a massive reduction in insulin release by the
destruction of the b-cells of the islets of langerhans, inducing
hyperglycaemia (Fisher, 1985). The diabetic rats (induced by
alloxan) showed a persistent rise in BGL after 7 days with
the characteristic features of diabetes mellitus. Traditional
plant medicines are used throughout the world for a range of
diabetic presentations the study of such medicines might offer
a natural key to unlock a diabetologist’s pharmacy for the fu-
ture. In light of this we made an attempt for the ﬁrst time to
study the effect of E. indica in normoglycaemic and hypergly-
caemic rats. Both the extracts of E. indica were not able to de-
crease the BGL in alloxan-induced diabetic rats, on single dose
administration which infers that the extracts are ineffective.
The signiﬁcant activity was attained on repeated administra-
tion of the AlcE and AqsE from day 7 by controlling the ele-
vated BGL compared with other group. In case of OGTT,
both the extracts on repeated administration improved glucose
tolerance in diabetic rats on 8th, 15th and 22nd days as com-
pared to diabetic control. While in case of AqsE (400 mg/kg) it
has shown a signiﬁcant reduction in the 6th hour and on 22nd
hour to that of the standard. Impaired glucose tolerance is at-
tained due to lack of insulin in alloxan-induced diabetic rats by
destructing the b-cells which leads to type I diabetes (Tanga
et al., 2006). From the present study it indicates that these ex-
tracts can improve the glucose tolerance, suggesting that theseextracts may show insulin mimetic activity or improved glu-
cose utilization mechanism. Glucosuria is the common symp-
tom of diabetes. It arises due to the increase in BGL above
250 mg/dl in diabetic animals. In our study we found that
the administration of both extracts to diabetic rats reversed
their blood glucose which was also reﬂected in their urine sugar
levels. The possible mechanism by which the extracts bring
about their anti-hyperglycaemic action may be by increasing
either pancreatic secretion of insulin from b cells or its release
from the bound form (Stanely et al., 2004). It is well estab-
lished that sulfonylureas produce hypoglycaemia by increasing
the secretion of insulin from pancreas and these compounds
are active in mild alloxan induced diabetes, whereas they are
inactive in intense alloxan diabetes (nearly all the beta cells
have been destroyed) (Krishna et al., 2004). In our work, no
histological study was carried out to explain the mechanism
of anti-diabetic action of E. indica. However, our results
showed that Glibenclamide reduced BGL in mild hyperglycae-
mic animals. The diabetic rats receiving the extracts of E. indi-
ca showed normalization of BGL compared to diabetic
control. This could be due to the possibility that some beta
cells are still surviving to exert their insulin releasing effect
by E. indica. Moreover, extracts produced hypoglycaemia in
normal rats also. This suggests that extracts are probably med-
iated by enhanced secretion of insulin like, sulfonylureas.
However, the possibility of enhanced tissue uptake byE. in-
dica cannot be ruled out. In addition, the glucose lowering ef-
fect of extracts was more powerful when compared to normal
rats suggesting that it could be caused by an increase in periph-
eral glucose consumption, this reinforces the hypothesis that
the hypoglycaemic mechanism involves insulin like effect
through peripheral glucose consumption, delay in insulin
catabolism or inhibition of glucose reabsorption by the kidney.
The fact that some herbal preparations enhances the beta cell
regeneration and peripheral glucose utilization in Alloxan and
Streptozotocin induced diabetic rats supports the above
assumption (Chakravarthy et al., 1982; Mitra et al., 1996). Ole-
anolic acid, a triterpenoids obtained from the stem bark lowers
the blood glucose in normal and diabetic mice. It is well known
that oxygen free radicals are involved in diabetogenic action of
alloxan and plants containing ﬂavonoids, isoﬂavanoids, trit-
erpenoids have been shown to be effective in diabetes due their
antioxidants property (Jafri et al., 2000; Syed et al., 2005). This
suggest that the anti-hyperglycaemic activity of E. indica may
be due to free radical scavenging activity which enhance the
beta cell regeneration against alloxan induced free radicals.
However, from the present experimental data it is difﬁcult to
42 A.Y. Kumar et al.say how exactly the mechanism of anti-diabetic activity of ex-
tracts of E. indica. It needs more elaborate study.
One of the major complication of type I diabetes is weight
loss. It arises due to the impairment in insulin action in the
conversion of glucose into glycogen and catabolism of fats,
inhibition of lipolysis due to its unavailability because of
destruction in beta cells (Gillespie, 2006). Due to this there will
be a decrease in the body weight of the animals and in death.
Treatment with extracts AlcE and AqsE has substantially pre-
vented the body weight loss and mortality produced by allox-
an. The results of BGL, glucose tolerance, urine sugar, body
weight and mortality are in correlation with each other and
indicate the AqsE and AlcE can be beneﬁcial in reducing the
effects of alloxan induced diabetes.
Dexamethasone results in hyperglycaemia due to an imbal-
ance of lipid metabolism leading to hyperlipidemia and an in-
crease in glucose level leading to hyperglycaemia.
Dexamethasone can cause metabolic changes resulting in de-
crease in food consumption and decrease in body weight. Pro-
found obesity due to alteration of ob gene expression often
associated with development of insulin resistance with en-
hanced BGL due to impairment of GLUT4 translocation (Bar-
bera et al., 2001; Ogawa et al., 1992). In the present study
treatment with dexamethasone for 10 days increases in BGL
and decreases the body weight similar to that of the previous
studies. Pretreatment with AqsE (200 and 400 mg/kg) 1 h be-
fore dexamethasone for 10 days had signiﬁcantly prevented
the rise in BGL caused by dexamethasone and also improved
glucose tolerance after glucose loading. AqsE (200 and
400 mg/kg) signiﬁcantly prevented the decrease in body weight
as compared with diabetic control.5. Conclusion
In conclusion, AqsE had shown a signiﬁcant hypoglycaemic
activity in normal rats, anti-diabetic activity against alloxan in-
duced and improved insulin resistance in dexamethasone in-
duced diabetic rats.Conﬂict of interest
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